Novartis taps Ratio for $745M radiopharmaceutical pact

Nov 15, 2024 · Novartis, Ratio sign radiopharmaceutical pact to the tune of $745M biobucks. Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth …

CouponFollow Extension

$745
OFF

Novartis Taps Ratio For $745M Radiopharmaceutical Pact

6 days from now

Nov 15, 2024 · Novartis, Ratio sign radiopharmaceutical pact to the tune of $745M biobucks. Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth …

fiercebiotech.com

$745
OFF

Novartis Invests $745M To Compete With BMS And Lilly In The …

6 days from now

4 days ago · Novartis has been aggressive in expanding its pipeline, acquiring Endocyte for $2 billion in 2018. Earlier this year, the company acquired Mariana Oncology for $1 billion and …

geneonline.com

$745
OFF

Novartis Continues Push Into Radiopharma With $745M Ratio Deal

6 days from now

5 days ago · With two approved radioligand therapies on its commercial roster and a recent plan to boost its manufacturing for radiotherapeutics, Novartis AG tapped Ratio Therapeutics Inc. in …

bioworld.com

$745
OFF

Ratio Therapeutics Lands $745M Cancer Drug Development Deal …

6 days from now

4 days ago · Ratio Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG to develop a Somatostatin Receptor 2 (SSTR2) …

stocktitan.net

$745
OFF

Novartis Signs Deal With Mass. Company Worth Up To $745M

6 days from now

4 days ago · Novartis’ interest in the hot area of radiopharmaceuticals is once again bringing it into contact with a Massachusetts company. ... Novartis signs deal with Mass. company worth …

bizjournals.com

$745
OFF

Novartis Expands Radiopharmaceutical Portfolio With $745M Deal …

6 days from now

5 days ago · Novartis has struck a licensing agreement with Boston-based biotech Ratio Therapeutics, securing global rights to a promising cancer candidate targeting somatostatin …

biopharmatrend.com

2%
OFF

Radiopharmaceuticals: A Niche But Growing Sector

6 days from now

2 days ago · The global radiopharmaceuticals market was estimated at $5.97 billion in 2023 and is expected to increase at a compound annual growth rate of 8.2% to reach $13.67 billion by …

dcatvci.org

$1
OFF

Novartis Entrenches Into Radiopharma With $1B Mariana Buy

6 days from now

By Annalee Armstrong May 2, 2024 7:00am. Novartis Mariana Oncology radiopharmaceuticals Pluvicto. With much still to discover in the massive world of radiopharmaceuticals, Novartis will …

fiercebiotech.com

$63
OFF

Novartis Strengthens Radiopharma Leadership With Ratio …

6 days from now

Venture financing for innovative radiopharmaceutical drugs witnessed an increase from $63m in 2017 to over $400m in 2023 total deal value in the US, according to GlobalData’s Pharma …

msn.com

$1
OFF

Novartis Deepens Radiopharma Presence With $1B Mariana …

6 days from now

Jun 26, 2024 · In a strategic move, Novartis has secured a $1 billion upfront acquisition of Mariana Oncology, a company established in 2021 with funding from Atlas Venture, Access …

patsnap.com

FAQs about Novartis taps Ratio for $745M radiopharmaceutical pact Coupon?

What is Novartis doing with radioligand therapy?

In the announcement accompanying the deal, Novartis’ president of biomedical research Fiona Marshall said: “Radioligand therapies hold transformative potential for certain forms of cancer, and Novartis is committed to maximising their impact by continually improving the benefit for patients.” ...

Does Novartis need a big move?

The CEO said the biotech didn’t need to make a big move like this after raising $175 million late last year in a series B, but Mariana had caught the attention of potential buyers. Novartis had recently been joined by peers Lilly and Bristol Myers Squibb in the radiopharmaceuticals space with plenty of deal action. ...

How much money will Novartis get from ratio?

As part of the agreement, Ratio stands to receive up to $745m in combined upfront and milestone payments, along with tiered royalties on sales. The collaboration focuses on preclinical research to identify an SSTR2-targeting development candidate, after which Novartis will take the lead on development, manufacturing, and commercialisation. ...

Does Novartis have a new RLT facility?

Novartis begins construction of two new radioligand therapy facilities in the US, expanding its world-class RLT manufacturing and supply network... ...

Will Novartis buy Mariana oncology?

With much still to discover in the massive world of radiopharmaceuticals, Novartis will take a deep dive into the unknown with Mariana Oncology in a $1 billion upfront acquisition. ...

What does Novartis do?

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Patients and caregivers ...